Company news
Cellectar Biosciences, Inc. news in 2023
Cellectar Biosciences, Inc.'s news releases, calls and decks from 2023, newest first.
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
December 18, 2023
Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform
December 11, 2023
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
December 4, 2023
Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
November 1, 2023
Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
October 24, 2023
Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023
October 23, 2023
Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia
October 16, 2023
Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
October 1, 2023
Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia
September 17, 2023
Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing
September 10, 2023
Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing
September 4, 2023
Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
August 13, 2023
Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting
June 27, 2023
Cellectar Provides a Research and Development Program Summary
June 11, 2023
Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
May 3, 2023
Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update
March 8, 2023
Cellectar to Participate at Upcoming Banking Conferences
March 7, 2023
Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient
February 27, 2023
Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical
February 14, 2023